BIIB Stock UPDATES Biogen Idec Inc (BIIB) 342.58 08/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biogen Idec Inc (BIIB) 342.58 $BIIB

What Investors Gain from Large, Mid & Small-Cap Growth Funds - Mutual Fund Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 2:02PM CDT
For investors looking to invest in growth funds, we will suggest here the top growth funds from each market capitalization. These funds carry a Zacks Mutual Fund Rank #1 (Strong Buy) as we expect the funds to outperform its peers in the future

Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 20, 10:08AM CDT
Last week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.

US Orphan Drug Clinical Pipeline Insight 2014 - New Report on the $49 Billion Industry
M2 - Wed Aug 20, 8:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q26z36/us_orphan_drug) has announced the addition of the "US Orphan Drug Clinical Pipeline Insight 2014" report to their offering. In 2013, the US market for orphan drugs was estimated worth US$ 49 Billion. With factors like government support, high profitability and many more, this market is expected to surpass US$ 60 Billion by 2018. The orphan drugs enjoy significant competitive advantages owing to the market exclusivity period after the drug has been authorized. Through this clause, the manufacturer of orphan drugs is given a monopoly status in the market because according to the law, no other company is allowed to market the orphan drugs during the exclusivity period. Additionally, this monopolistic power is further strengthened with the fact that no other alternative health technology exists for many orphan drugs. In US, the research & development of orphan drugs is facilitated by public programs, government regulations, and policies. The major incentives for research & development of orphan drug include grants, research support, fee waivers, tax incentives, and orphan drug market exclusivity. In a highly specialized market like that of orphan drugs, though the impact of market exclusivity in the US has been positive yet relatively modest, a special platform for continued orphan drug development has been laid down by the economic incentives and public support mechanisms. US Orphan Drug Pipeline Insight 2014 - Report Highlight: - US Orphan Drug Market Insight & Orphan Drug Designation Criteria - Reimbursement Policy & FDA Regulatory Framework - US Orphan Drug Pipeline by Phase, Indication & Company - Marketed Orphan Drug Clinical Insight - US Orphan Drug Clinical Pipeline: 570 Drugs - Marketed Orphan Drugs in US: 203 Drugs - Majority Orphan Drugs in PHASE-II Development: 207 Drugs Key Topics Covered: 1. Introduction to US Orphan Market - Market Overview - Clinical Pipeline Overview 2. US Orphan Drug Regulatory Framework - Criteria for Orphan Drug Designation - Reimbursement Policy for Orphan Drugs - FDA Regulation 3. US Orphan Drug Clinical Pipeline by Phase, Indication & Company - Unknown - Research - Preclinical - Clinical - Phase-I - Phase-I/II - Phase-II - Phase-II/III - Phase-III - Preregistration - Registered 4. Marketed Orphan Drugs Clinical Insight by Indication & Company 5. Suspended & Discontinued Orphan Drugs in Clinical Pipeline by Phase, Indication & Company - No development reported - Discontinued - Market Withdrawal - Suspended 6. Competitive Landscape - Alexion - Biogen Idec - Bristol Myers Squibb - Celgene - Eli Lilly - Glaxosmithkline - Merck - Novartis Pharmaceuticals - Pfizer - Roche - Rare Disease Therapeutics - Sanofi For more information visit http://www.researchandmarkets.com/research/q2...rphan_drug

Drug Approvals, Clinical Trial Result, and Philanthropic Activity - Research Reports on Johnson & Johnson, Biogen, Amgen, Medtronic and Merck
PR Newswire - Wed Aug 20, 8:20AM CDT
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Biogen Idec Inc. (NASDAQ: BIIB), Amgen, Inc. (NASDAQ: AMGN), Medtronic, Inc. (NYSE: MDT) and Merck (NYSE: MRK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5855-100free.

Biogen Strengthens MS Portfolio with Plegridy FDA Approval - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 19, 12:20PM CDT
Plegridy's less frequent dosing schedule could help it gain share from other beta interferon treatments.

Biogen's buy rating reaffirmed
at Investor's Business Daily - Mon Aug 18, 5:40PM CDT
The biotech's overweight or buy rating was reaffirmed by Morgan Stanley on the FDA's approval of Biogen's (BIIB) new Plegridy drug for people with multiple sclerosis on Fri. The new treatment is a long-lasting form of the company's Avonex drug and...

Why Biogen Idec (BIIB) Stock Is Gaining Today
at The Street - Mon Aug 18, 10:44AM CDT
Biogen Idec (BIIB) shares are climbing on Monday after the company's relapsing multiple sclerosis drug treatment, Plegridy, was approved by the FDA.

Isis Pharmaceuticals earns USD2m for advancement of ISIS-SMN Rx in children with SMA from Biogen Idec
M2 - Mon Aug 18, 7:20AM CDT
Drug company Isis Pharmaceuticals (NasdaqGS:ISIS) reported on Friday the receipt of a USD2m milestone payment from Biogen Idec related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy (SMA).

Biogen Idec awarded US FDA approval for PLEGRIDY for treating multiple sclerosis
M2 - Mon Aug 18, 5:33AM CDT
Medicine company Biogen Idec (NasdaqGS:BIIB) reported on Friday the receipt of approval from the US Food and Drug Administration (FDA) for treating people with relapsing forms of multiple sclerosis (RMS) with the new subcutaneous injectable therapy, PLEGRIDY.

FDA approves Biogen's MS drug Plegridy
AP - Fri Aug 15, 6:27PM CDT
CAMBRIDGE, Mass. (AP) — Biogen Idec says that federal regulators have approved the specialty drugmaker's new treatment for people with relapsing forms of multiple sclerosis.

Biogen Idec's PLEGRIDY(TM)(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis
Business Wire - Fri Aug 15, 5:44PM CDT
--a^' Only Pegylated Interferon in MS, Dosed Once Every Two Weeks -

Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 1.62% Rise
Comtex SmarTrend(R) - Fri Aug 15, 3:45PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $330.70 to a high of $343.03. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $338.51 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Biogen Idec Rises 1.62% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Aug 15, 3:45PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $330.70 to a high of $343.03. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $338.51 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Today's Momo Momentum Stock Is Biogen Idec (BIIB)
at The Street - Fri Aug 15, 8:49AM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate

Isis Pharmaceuticals Earns $2M from the Advancement of ISIS-SMN Rx in Children with Spinal Muscular Atrophy
PR Newswire - Fri Aug 15, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2 million milestone payment from Biogen Idec related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy (SMA).

Global Biological Drugs Market 2014 - 2020 - Industry Analysis for the $161.056 Million Industry
M2 - Fri Aug 15, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hjz57l/biological_drugs) has announced the addition of the "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global biological drugs market is estimated at USD 161,056.5 million in 2014 and is expected to grow at a CAGR of 10.1% from 2014 to 2020, to reach USD 287,139.7 million by 2020 The report provides in-depth analysis and estimation of the biological drugs market from 2014 to 2020, considering 2013 as the base year for calculation. Additionally, data pertaining to current market dynamics including market drivers, restraints, trends and recent developments has been provided in the biological drugs market report. The global biological drugs market is categorized based on therapeutic protein, monoclonal antibody (mAb), vaccine and geography. The therapeutic protein segmentation is further sub-segmented into Enbrel, Lantus, Neulasta, Avonex, NovoLog, Rebif, Humalog, Aranesp, Epogen, Levemir, Victoza, Betaseron, Neupogen, and Eylea. The mAb segment comprises Humira, Remicade, Rituxan, Avastin, Herceptin and Lucentis. The vaccine segment is further sub-segmented into Prevnar 13, Gardasil, Fluzone, Varivax and Cervarix. Globally, the biological drugs market is witnessing a significant growth due to increasing prevalence of various chronic diseases, as the demand for biological drugs is increasing with the rise in the global geriatric population. The biological drugs are used in the treatment and prevention of various diseases, such as blood related diseases, cancer, auto-immune diseases and other medical disorders. Additionally, various government associations are promoting the usage of biological drugs. Moreover, advancement in biomedical sciences holds immense potential for the growth of the biologic drugs market. North America is the largest market for biological drugs. Enbrel is the largest and fastest growing therapeutic protein. In monoclonal antibody (mAb), Humira is the largest and fastest growing mAb. Prevnar 13 is the largest and fastest growing vaccine. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Biological Drugs Market - Industry Analysis Chapter 4 Market Trends Chapter 5 Porter's Five Forces Analysis Chapter 6 Global Market Size and Forecast Chapter 7 Segment Analysis, by Therapeutic Protein Chapter 8 Segment Analysis, by mAb Chapter 9 Segment Analysis, by Vaccine Chapter 10 Regional Analysis Chapter 11 Pipeline Biologic Drugs Chapter 12 Competitive Landscape Chapter 13 Company Profiles - Abbott Laboratories - Amgen Inc. - Baxter International Inc. - Biogen Idec - Bristol-Myers Squibb Company - Eli Lilly and Company - GlaxoSmithKline plc. - Merck & Co., Inc. - Novartis AG - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/hj...ical_drugs

Perrigo Beats on Q4 Earnings and Sales, Provides Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 12:29PM CDT
Perrigo (PRGO) reported higher than expected earnings and revenues in the fourth quarter.

Biotech, Social Media Stocks Are Less Frothy Than Janet Yellen Thinks
at The Street - Thu Aug 14, 11:34AM CDT
A month after Fed Chair Janet Yellen's comments, ETFs covering both groups are pushing towards new highs on strong fundamental backdrops.

Perrigo Q4 Beats Estimates, But Guidance Misses
at Investor's Business Daily - Thu Aug 14, 10:02AM CDT
Drugmaker Perrigo (PRGO) beat Wall Street's Q4 expectations Thursday morning, sending the stock up 6% on the stock market today even though its 2015 guidance missed estimates. Sales for the quarter ended June 28 rose 18% over the year-earlier quarter...




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Adcendo’s Early Sarcoma Data Earns a Careful Look

Updated Category News Views 22

Sarcoma data rarely gives anyone permission to pound the table, yet Adcendo’s first look at ADCE-D01 deserves more than a polite nod. In advanced soft tissue sarcoma, where patients have often run through the usual options and second-line response rates historically sit around 4% to 10%, a reported 30% objective response rate on the every-two-week schedule is...

Continue Reading
BetterInvesting Puts ELMD and FIVE Under a Fresh Lens

Updated Category News Views 90

Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is...

Continue Reading
GFT's Banking Leader Tag Puts Execution Risks Into Focus

Updated Category News Views 39

A banking overhaul is where glossy slides go to die. That is why GFT Technologies being named a Leader in QKS Group's 2026 SPARK Matrix for Digital Banking Services deserves a little more attention than the usual analyst-firm trumpet blast. This is not a prize for making a pretty mobile app. The work described here runs through strategy, architecture, core-platform...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 51

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading
American Pride Bank Tests a Fast Southeast Expansion

Updated Category News Views 197

Those old Winston-Salem smokestacks make a fitting backdrop for a bank trying to build something new, and American Pride Bank is moving with uncommon speed. Its new office at 450 N. Patterson Ave., Suite 200 sits in the Bailey South building in Innovation Quarter, across from Bailey Park and amid a district deliberately remade for founders, researchers and growing...

Continue Reading
Housing's Value Equation Is Getting More Complicated

Updated Category News Views 100

A homeowner's insurance bill has become a louder market signal than a granite countertop. Green Builder Media's latest batch of research, publishing and events is aimed squarely at that uncomfortable truth: housing is no longer judged only by the price on the contract. Buyers, builders, lenders and insurers are being pushed to reckon with what a home costs to own, protect...

Continue Reading
NYSE Message Record Puts Market Plumbing Into Focus

Updated Category News Views 60

A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...

Continue Reading
EmTech AI 2027 Puts AI Ambitions Through Reality Test

Updated Category News Views 21

A three-day gathering cannot settle AI's biggest arguments, but MIT Technology Review has picked the right fight for EmTech AI 2027: make the industry face a Reality Test. The conference runs May 11–13, 2027, at MIT's campus and online, and that theme lands because the AI conversation has spent plenty of time admiring the engine while skipping the ugly maintenance bill....

Continue Reading
Miami I20 Tests Appetite for Long-Term U.S. Capital

Updated Category News Views 194

Five days in a Miami airport hotel may not sound like the machinery of national investment policy, yet the guest list for the inaugural I20 Summit is serious enough to make capital markets sit up. From December 11 through 15, the Sovereign Wealth Fund Institute plans to bring sovereign funds, pensions, endowments, family offices, business leaders and U.S....

Continue Reading
Yunnan Tin’s AI Materials Push Has Real Operating Teeth

Updated Category News Views 13

Tin rarely gets the spotlight until the machinery behind modern computing starts demanding more of it. Yunnan Tin Group is making the sensible case that this unglamorous metal can matter a great deal in semiconductors, artificial intelligence infrastructure and new-energy hardware. There is plenty of corporate ambition wrapped around that case, naturally, but a few...

Continue Reading

Top 5 Most Recently Viewed Articles

AXIA Time Launches New College Football Playoff Limited Edition

Updated Category News Views 81

Introducing AXIA Time's New College Football Playoff Collection AXIA Time is making waves with its expanded partnership with the College Football Playoff (CFP) and the launch of a fantastic new collection. Known for its high-quality craftsmanship, AXIA Time has introduced a series of limited edition, heirloom-quality watches specifically created for the 2025 College...

Continue Reading
Uphold Launches Staking Services for UK Users Amid Changes

Updated Category News Views 375

Uphold Introduces Staking Features for UK Customers Customers of Uphold can now take advantage of staking rewards on their crypto assets. This major shift comes after the UK Treasury amended the Financial Services and Markets Act, allowing crypto-asset service providers to offer staking services to individuals and businesses within the United Kingdom. Impact of Regulatory...

Continue Reading
ASDS Annual Conference: Elevating Dermatology Education for 2025

Updated Category News Views 196

Registration Now Open for 2025 ASDS Annual Conference The American Society for Dermatologic Surgery (ASDS) has announced the opening of registration for its highly anticipated annual meeting. This prestigious event gathers dermatologists and their staff for a four-day immersive experience aimed at improving skills and knowledge in dermatologic surgery. The conference will...

Continue Reading
Revolutionizing Order Management with OMS+ Cloud Solution

Updated Category News Views 212

DataXstream Unveils OMS+ Cloud Solution for Enhanced Order Management DataXstream LLC has rolled out its latest innovation, the OMS+ Cloud specifically designed for SAP S/4HANA Cloud Public Edition, aiming to transform how businesses manage their sales and order processes. Transforming Sales and Order Processes For more than a decade, OMS+ has been at the forefront of...

Continue Reading
Innovative Paper Towel Stand Redefines Hygiene and Convenience

Updated Category News Views 170

Revolutionary Design for Paper Towel Dispensing In a world where hygiene is paramount, a visionary inventor from Oakgrove has developed an innovative solution known as the Adjustable Paper Towel Stand. This unique accessory is designed to dispense paper towels one at a time, effectively minimizing contact with the entire roll, which can often lead to contamination and...

Continue Reading